Customizable Zr-MOF nanoantidote-based multieffective arsenic detoxification and its extended low-toxic therapy
Acta Biomaterialia · 2024-07 · 182 · 228-244
DOI: 10.1016/j.actbio.2024.05.027 ↗Kurz gefasst
Fachartikel in der Zeitschrift Acta Biomaterialia, 2024-07. Verfasst von Yanhua Zhong und 8 weiteren Autor:innen. Beteiligte Einrichtung: School of Chemistry and Chemical Engineering of Nanchang University, Nanchang 330088, China. Hauptthemen laut MEDLINE: Metal-Organic Frameworks, Zirconium, Arsenic, Arsenic Poisoning. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 67 Literaturangaben. Gefördert von: Nanchang University, Key Research and Development Program of Jiangxi Province.
Abstract (Originalsprache)
Arsenic (As) poisoning has become a global public problem threatening human health. Chelation therapy (CT) is the preferred treatment for arsenic poisoning. Nevertheless, efficient and safe arsenic removal in vivo remains a daunting challenge due to the limitations of chelators, including weak affinity, poor cell membrane penetration, and short half-life. Herein, a mercapto-functionalized and size-tunable hierarchical porous Zr-MOF (UiO-66-TC-SH) is developed, which possesses abundant arsenic chemisorption sites, effective cell uptake ability, and long half-life, thereby efficiently removing toxic arsenic in vivo. Moreover, the strong binding affinity of UiO-66-TC-SH for arsenic reduces systemic toxicity caused by off-target effects. In animal trials, UiO-66-TC-SH decreases the blood arsenic levels of acute arsenic poisoning mice to a normal value within 48 h, and the efficacy is superior to clinical drugs 2,3-dimercaptopropanesulfonic acid sodium salt (DMPS). Meanwhile, UiO-66-TC-SH also significantly mitigates the arsenic accumulation in the metabolic organs of chronic arsenic poisoning mice. Surprisingly, UiO-66-TC-SH also accelerates the metabolism of arsenic in organs of tumor-bearing mice and alleviates the side effects of arsenic drugs antitumor therapy. STATEMENT OF SIGNIFICANCE: Arsenic (As) contamination has become a global problem threatening public health. The present clinical chelation therapy (CT) still has some limitations, including the weak affinity, poor cell membrane permeability and short half-life of hydrophilic chelators. Herein, a metal-organic framework (MOF)-based multieffective arsenic removal strategy in vivo is proposed for the first time. Mercapto-functionalized and size-tunable hierarchical porous Zr-MOF nanoantidote (denoted as UiO-66-TC-SH) is accordingly designed and synthesized. After injection, UiO-66-TC-SH can form Zr-O-As bonds and As-S bonds with arsenic, thus enhancing arsenic adsorption capacity, cycling stability and systemic safety simultaneously. The acute arsenic poisoning model results indicate that UiO-66-TC-SH shows superior efficacy to the clinical drug sodium dimercaptopropanesulfonate (DMPS). More meaningfully, we find that UiO-66-TC-SH also accelerates the metabolism of arsenic in organs of tumor-bearing mice and alleviates side effects of arsenic drugs anti-tumor therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Chemistry and Chemical Engineering of Nanchang University, Nanchang 330088, China.
- School of Chemistry and Chemical Engineering of Nanchang University, Nanchang 330088, China; Postdoctoral Innovation Practice Base, The First Affiliated Hospital of Nanchang University, Nanchang 330006, China.
- The National Engineering Research Center for Bioengineering Drugs and the Technologies, Institute of Translational Medicine, Nanchang University, Nanchang 330088, China.
- School of Chemistry and Chemical Engineering of Nanchang University, Nanchang 330088, China; The National Engineering Research Center for Bioengineering Drugs and the Technologies, Institute of Translational Medicine, N…
Förderung
- Nanchang University
- Key Research and Development Program of Jiangxi Province
Zitieren
APA
Zhong, Y., Zhang, W., Xiao, H., Kong, Y., Huang, W., Bai, D., Yu, S., Gao, J., & Wang, X. (2024). Customizable Zr-MOF nanoantidote-based multieffective arsenic detoxification and its extended low-toxic therapy. Acta Biomaterialia, 182, 228-244. https://doi.org/10.1016/j.actbio.2024.05.027
Vancouver
Zhong Y, Zhang W, Xiao H, Kong Y, Huang W, Bai D, et al. Customizable Zr-MOF nanoantidote-based multieffective arsenic detoxification and its extended low-toxic therapy. Acta Biomaterialia. 2024;182:228-244. doi:10.1016/j.actbio.2024.05.027
BibTeX
@article{Zhong2024,
author = {Zhong, Yanhua and Zhang, Wei and Xiao, Hong and Kong, Yijie and Huang, Wenjing and Bai, Danmeng and Yu, Simin and Gao, Jie and Wang, Xiaolei},
title = {Customizable Zr-MOF nanoantidote-based multieffective arsenic detoxification and its extended low-toxic therapy},
journal = {Acta Biomaterialia},
year = {2024},
volume = {182},
pages = {228--244},
doi = {10.1016/j.actbio.2024.05.027}
}
EUVIMED